Colorimetric Determination of Cefadroxil and Ceftriazone in Pharmaceutical Dosage Forms

Purpose: To develop a simple, rapid and selective method for the spectrophotometric determination of cefadroxil and ceftriaxone using 1, 2- napthaquinone-4- sulfonic acid sodium.Methods: The method was based on the derivatization of cefadroxil and ceftriaxone with 1, 2-naphthaquinone-4- sulfonic acid sodium in alkaline medium to yield orange-colored products.Results: The reaction products of cefadroxil and ceftriaxone at their respective max of 475 and 480 nm showed linearity in the concentration range of 10 - 100 and 25 - 175 ìg/ml, respectively. Relative standard deviations of 0.82 % for cefadroxil and 0.95 % for ceftriaxone were obtained. Recoveries of cefadroxil tablets and ceftriaxone injection were in the range of 100.66 ± 0.98 and 99.38 ± 0.84 %, respectively.Conclusion: Recovery studies gave satisfactory results indicating that none of the major additives/excipients interfered with the assay method. Therefore, the proposed method is simple, rapid, precise and convenient for the assay of cefadroxil and ceftriaxone in commercial preparations

Neuroinflammatory and demyelinating disorders of childhood

In this chapter, we will review monophasic and recurrent demyelinating disorders in children. We will first review consensus definitions and provide an approach to the evaluation of children with first episode of acquired demyelinating disorder. We will discuss typical clinical and radiological features of these syndromes. In the second section, we will review features of recurrent demyelinating syndromes in children, focusing on clinical presentation and treatment options

Neuroinflammatory and demyelinating disorders of childhood

In this chapter, we will review monophasic and recurrent demyelinating disorders in children. We will first review consensus definitions and provide an approach to the evaluation of children with first episode of acquired demyelinating disorder. We will discuss typical clinical and radiological features of these syndromes. In the second section, we will review features of recurrent demyelinating syndromes in children, focusing on clinical presentation and treatment options